Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 459

1.

Molecular targeted treatment of metastatic colorectal cancer: the cardiovascular adverse effects of Bevacizumab and Cetuximab.

Gherman A, Căinap C, Constantin AM, Cetean S, Căinap SS.

Clujul Med. 2017;90(4):377-384. doi: 10.15386/cjmed-745. Epub 2017 Oct 20. Review.

2.

Real-world treatment patterns and effectiveness among patients with metastatic colorectal cancer treated with ziv-aflibercept in community oncology practices in the USA.

Ivanova JI, Saverno KR, Sung J, Duh MS, Zhao C, Cai S, Vekeman F, Peevyhouse A, Dhawan R, Fuchs CS.

Med Oncol. 2017 Nov 4;34(12):193. doi: 10.1007/s12032-017-1049-4.

3.

KRAS mutation and primary tumor location do not affect efficacy of bevacizumab-containing chemotherapy in stagae IV colorectal cancer patients.

Sun DC, Shi Y, Wang YR, Lv Y, Yan H, Mao H, Wang ZK, Wu ZY, Shi WW, Dai GH.

Sci Rep. 2017 Oct 30;7(1):14368. doi: 10.1038/s41598-017-14669-2.

4.

Pharmacogenomics DNA Biomarkers in Colorectal Cancer: Current Update.

Ab Mutalib NS, Md Yusof NF, Abdul SN, Jamal R.

Front Pharmacol. 2017 Oct 12;8:736. doi: 10.3389/fphar.2017.00736. eCollection 2017. Review.

5.
6.

The addition of bevacizumab in the first-line treatment for metastatic colorectal cancer: an updated meta-analysis of randomized trials.

Jang HJ, Kim BJ, Kim JH, Kim HS.

Oncotarget. 2017 Aug 17;8(42):73009-73016. doi: 10.18632/oncotarget.20314. eCollection 2017 Sep 22.

7.

Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational study.

Wang X, Wei Q, Gao J, Li J, Li J, Gong J, Li Y, Shen L.

Chin J Cancer. 2017 Oct 16;36(1):81. doi: 10.1186/s40880-017-0247-y.

8.

Erlotinib in combination with bevacizumab and FOLFOX4 as second-line chemotherapy for patients with metastatic colorectal cancer.

Shi S, Lu K, Gao H, Sun H, Li S.

Am J Cancer Res. 2017 Sep 1;7(9):1971-1977. eCollection 2017.

9.

An Update on Randomized Clinical Trials in Metastatic Colorectal Carcinoma.

Ikoma N, Raghav K, Chang G.

Surg Oncol Clin N Am. 2017 Oct;26(4):667-687. doi: 10.1016/j.soc.2017.05.007. Epub 2017 Aug 4. Review.

PMID:
28923224
10.

Bevacizumab significantly increases the risks of hypertension and proteinuria in cancer patients: A systematic review and comprehensive meta-analysis.

Zhao T, Wang X, Xu T, Xu X, Liu Z.

Oncotarget. 2017 May 23;8(31):51492-51506. doi: 10.18632/oncotarget.18190. eCollection 2017 Aug 1.

11.

Impact of second-line cetuximab-containing therapy in patients with KRAS wild-type metastatic colorectal cancer: results from the ITACa randomized clinical trial.

Passardi A, Scarpi E, Gelsomino F, Palladino MA, Casadei Gardini A, Turci D, Chiuri VE, Mucciarini C, Tassinari D, Ragazzini A, Frassineti GL, Valgiusti M, Ulivi P, Amadori D.

Sci Rep. 2017 Sep 5;7(1):10426. doi: 10.1038/s41598-017-11048-9.

12.

Cardiovascular Adverse Events in Patients With Cancer Treated With Bevacizumab: A Meta-Analysis of More Than 20 000 Patients.

Totzeck M, Mincu RI, Rassaf T.

J Am Heart Assoc. 2017 Aug 10;6(8). pii: e006278. doi: 10.1161/JAHA.117.006278. Review.

13.

Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9.

Winther SB, Österlund P, Berglund Å, Glimelius B, Qvortrup C, Sorbye H, Pfeiffer P; - on behalf of the Academy of Geriatric Cancer Research (AgeCare).

BMC Cancer. 2017 Aug 16;17(1):548. doi: 10.1186/s12885-017-3526-8.

14.

Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars.

Rosen LS, Jacobs IA, Burkes RL.

Target Oncol. 2017 Oct;12(5):599-610. doi: 10.1007/s11523-017-0518-1. Review.

15.

Present and future of metastatic colorectal cancer treatment: A review of new candidate targets.

Martini G, Troiani T, Cardone C, Vitiello P, Sforza V, Ciardiello D, Napolitano S, Della Corte CM, Morgillo F, Raucci A, Cuomo A, Selvaggi F, Ciardiello F, Martinelli E.

World J Gastroenterol. 2017 Jul 14;23(26):4675-4688. doi: 10.3748/wjg.v23.i26.4675. Review.

16.

Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer: Regimen of 1 week on, 1 week off.

Li J, Xu R, Xu J, Denda T, Ikejiri K, Shen L, Toh Y, Shimada K, Kato T, Sakai K, Yamamoto M, Mishima H, Wang J, Baba H.

Cancer Sci. 2017 Oct;108(10):2045-2051. doi: 10.1111/cas.13335. Epub 2017 Sep 9.

17.

European Medicines Agency approval summary: Zaltrap for the treatment of patients with oxaliplatin-resistant metastatic colorectal cancer.

Stanel SC, Sjöberg J, Salmonson T, Foggi P, Caleno M, Melchiorri D, Gravanis I, Tzogani K, Pignatti F.

ESMO Open. 2017 May 2;2(2):e000190. doi: 10.1136/esmoopen-2017-000190. eCollection 2017. Review.

18.

Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM).

Salvatore L, Aprile G, Arnoldi E, Aschele C, Carnaghi C, Cosimelli M, Maiello E, Normanno N, Sciallero S, Valvo F, Beretta GD.

ESMO Open. 2017 Apr 12;2(1):e000147. doi: 10.1136/esmoopen-2016-000147. eCollection 2017. Review.

19.

A phase II clinical study of combining FOLFIRI and bevacizumab plus erlotinib in 2nd-line chemotherapy for patients with metastatic colorectal cancer.

Zhao Z, Li J, Ye R, Wu X, Gao L, Niu B.

Medicine (Baltimore). 2017 Jul;96(30):e7182. doi: 10.1097/MD.0000000000007182.

20.

Effect of adjuvant chemotherapy after pulmonary metastasectomy on the prognosis of colorectal cancer.

Shiomi K, Naito M, Sato T, Nakamura T, Nakashima H, Naito M, Mikubo M, Matsui Y, Watanabe M, Satoh Y.

Ann Med Surg (Lond). 2017 Jun 20;20:19-25. doi: 10.1016/j.amsu.2017.06.026. eCollection 2017 Aug.

Supplemental Content

Support Center